| The standard use of antibodies to assay FFPE tissue in the clinic generates semi-quantitative results, at best. To address this limitation, we have developed a Liquid Tissue®-SRM technology platform, which enables relative and absolute quantification of proteins and their phosphorylation status directly in FFPE tissue. Here we describe the clinical validation of a multiplexed EGFR diagnostic assay in a cohort of 40 archival FFPE colorectal cancer tumors from Cetuximab treated patients. This multiplexed assay measures EGFR, as well as additional targets (IGF1R, cMet, Ereg, etc.) that should be useful in predicting patient response to EGFR inhibitor therapy. |
|
